Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Observed-Blind, Randomized, Multi-center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.

NCT02255279 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT02255279
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02255279 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Observed-Blind, Randomized, Multi-center Study to Evaluate Safety and Immunogenicity of an Adjuvanted Trivalent Influenza Vaccine in Children 6 to <72 Months of Age in Mexico.
Lead sponsor
Novartis Vaccines
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2014
Completion date
May 31, 2015
Enrollment
287 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

influenza